VIVISOL acquires minority share of SOMNOmedics GmbH

First success in the conversion of SOMNOmedics to a stock corporation

 Randersacker, October 5, 2023. SOMNOmedics, a family-owned manufacturer dedicated to sleep diagnostic devices, has set its course for a secure future through initiation its conversion from a GmbH (limited liability company) into a stock corporation, the majority of which, however, remains in family ownership.

After the conversion into a stock corporation, 25% of the shares will be used to implement charitable projects in the ANNE Foundation.

To set the paths for the conversion, a strategic minority share of 15% of SOMNOmedics is acquired as of today by VIVISOL with the prospect to strengthen its strategic presence in the Home Care field. VIVISOL is part of the SOL-group, a multinational operating company both in the technical, industrial, and medicinal gases division as well as in the home care division.

For years, VIVISOL has been one of SOMNOmedics strongest partners in various European countries. With this involvement, SOMNOmedics and VIVISOL will consolidate and intensify their cooperation for the future.

SOMNOmedics and VISISOL: Setting the course for the future


Claudio Garbellini, Vice General Manager of SOL Group and responsible of the Home Care activities, commented: “our close cooperation with SOMNOmedics is successfully dating back many years so that the decision of becoming shareholders developed very naturally. This partnership confirms our willingness to continue growing in the field of sleep apnea disorders.”

Dr. Gert Küchler (Founder & CEO SOMNOmedics) comments: “With this important step we will strengthen our strategic cooperation which is already running successfully in more than five European countries, and we win our first shareholder after the transition from a GmbH to a stock company. The strong connection between sleep diagnostic and therapy is clearly a benefit for physicians, patients and of course for both companies in the sleep market. Vivisol is a family-based company and breathes the same spirit as SOMNOmedics.


Leading up to the acquisition of the minority share, SOMNOmedics and VIVISOL have already taken advantages of synergy effects in the field of patient care. To optimise internal workflows, SOMNOmedics has transferred the care of a share of patients in a one-off operation to VIVISOL earlier in 2023. SOMNOmedics will continue to expand this business area in the future.

Founded by Dr. Gert Küchler in 2000 as a start-up, SOMNOmedics has developed in the last 23 years to a market leader in the sector of sleep diagnostic thanks to a constant innovation and excellence of their products. In the year 2022 SOMNOmedics GmbH has recorded sales for 20 Mio Euro and was employing approx. 140 people. Today, SOMNOmedics is a leading company in sleep diagnostic with global activities and operations in more than 45 countries.

During the last years, SOMNOmedics has expanded its reach with the development of new diagnostic equipment for cardiology, neurology, anaesthesiology, and intensive care, and therefore set the path to become a global manufacturer for medical diagnostics. So far SOMNOmedics is on the way from the specialist in sleep diagnostic to a global provider of medical diagnostic devices.